Current Status of Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma

Authors

  • Xinhao Chen Department of Oncology, Laboratory of Immunity, Inflammation & Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
  • Runtian Xiao Department of Oncology, Laboratory of Immunity, Inflammation & Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
  • Tao Zhang Department of Oncology, Laboratory of Immunity, Inflammation & Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Keywords:

locally advanced nasopharyngeal carcinoma, induction chemotherapy

Abstract

Nasopharyngeal carcinoma (NPC) has a unique endemic distribution in the world, with the highest incidence rate in South China, Southeast Asia and North Africa. About 70% of newly diagnosed nasopharyngeal carcinoma patients suffer from locally advanced diseases. The current methods of radiotherapy and chemotherapy include synchronous radiotherapy and chemotherapy, induction chemotherapy, and adjuvant chemotherapy. Induction chemotherapy has better tolerance, so higher drug concentrations can be used to improve the survival rate of locally advanced nasopharyngeal carcinoma patients. Induction chemotherapy can eliminate micro metastatic diseases early. This article provides a review of the application of induction chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma.

Downloads

Published

2025-04-30

How to Cite

Xinhao Chen, Runtian Xiao, & Tao Zhang. (2025). Current Status of Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma. ournal of nnovations in edical esearch, 4(2), 59–65. etrieved from https://www.paradigmpress.org/jimr/article/view/1603

Issue

Section

Articles